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Abstract The dystrophin-glycoprotein complex (DGC) is crit-
ical for muscle membrane stability. The sarcoglycans are
transmembrane proteins within the DGC, and the function of
the sarcoglycans is unknown. Mutations in sarcoglycan genes
cause autosomal recessive muscular dystrophy. We have
identified a new sarcoglycan gene with high homology to K-
sarcoglycan highlighting the redundancy of the DGC. This gene,
named O-sarcoglycan, has an identical intron-exon structure to K-
sarcoglycan, and is more broadly expressed. The characteriza-
tion of O-sarcoglycan should make it possible to determine if it,
like the other sarcoglycan genes, is mutated in muscular
dystrophy.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
Muscular dystrophies arise from mutations in the genes
encoding dystrophin and its associated proteins [1,2]. In skel-
etal muscle, dystrophin associates with a complex of mem-
brane-associated proteins forming the dystrophin-glycoprotein
complex (DGC) [3,4]. The DGC is composed of a number of
proteins and binds the extracellular matrix protein laminin [5].
It is hypothesized that defects in the DGC disrupt the me-
chanical link between the cytoskeleton of muscle and the ex-
tracellular matrix. This disruption leads to membrane insta-
bility, myocyte necrosis and progressive replacement of the
muscle by connective and adipose tissue. Over time, the
muscle becomes progressively weakened resulting in the clin-
ical spectrum of muscular dystrophy. The exact molecular
mechanism that causes myocyte necrosis is unknown. More-
over, it is unknown why some muscles are more a¡ected than
others since the DGC appears to be present in all muscles.
One of the major DGC proteins, dystroglycan, binds dys-
trophin’s carboxy-terminus, spans the sarcolemma and inter-
acts with laminin in the extracellular matrix [5]. Sarcoglycan,
another major component of the DGC is composed of at least
four subunits, K, L, Q and N. In contrast to dystroglycan, K-, Q-
and N- sarcoglycan are exclusively expressed in striated
muscle, and patients with mutations exhibit a muscle pheno-
type (for reviews, see [1,2]). L-Sarcoglycan mRNA is expressed
at low levels in tissues other than striated muscle, but patients
with loss of function mutations in the L-sarcoglycan gene also
have classic proximal muscle weakness and muscular dystro-
phy [1,2]. The sarcoglycan subunits are thought to form a
subcomplex within the DGC since, in the presence of L-octyl
glucoside, the sarcoglycan subunits preferentially associate.
Mutations in any one of the sarcoglycan genes lead to a sec-
ondary instability of the other sarcoglycan subunits [1,2,6].
In this report, we describe a novel sarcoglycan gene. This
gene, O-sarcoglycan, is homologous to K-sarcoglycan [7,8], but
unlike K-sarcoglycan, O-sarcoglycan is expressed in other tis-
sues in addition to heart and skeletal muscle. The gene struc-
ture is conserved between K- and O-sarcoglycan with nearly
identical placement of the intron-exon borders, but signi¢-
cantly larger intronic distances. O-Sarcoglycan maps to 7q21,
and the murine gene for O-sarcoglycan maps to the syntenic
region on mouse chromosome 6. A processed pseudogene,
pseudo-O-sarcoglycan, is present on chromosome 2 in the hu-
man. The high homology of O-sarcoglycan to K-sarcoglycan
and its tissue expression argue that O-sarcoglycan may be a
component of the DGC not only in striated muscle but also in
non-muscle tissues. The knowledge of the map location, se-
quence and intron-exon borders should facilitate understand-
ing the role of O-sarcoglycan in muscular dystrophy.
2. Materials and methods
2.1. Identi¢cation of O-sarcoglycan cDNA and genomic sequences
Primers designed to the EST N44285 (5P-GACGGGAAGGCGTG-
GAAAAGAGAA-3P and 5P-AGCACTGTGATGGACCAGTTGG-
3P) were used in a PCR reaction with reverse transcribed total RNA
from human skeletal and cardiac muscle. The PCR product was ream-
pli¢ed to generate a radiolabeled fragment that was used to screen a
human genomic EMBL3 library (Clontech) and a human cardiac
cDNA library [8]. A full length cDNA clone was subcloned into Blue-
script and sequenced on both strands. DNA from genomic phage
clones encoding O-sarcoglycan was prepared as described [9] and
used as a template in cycle sequencing to determine intron-exon bor-
ders. Cycle sequencing was performed on an ABI 377 automated
sequencer. Sequences were analyzed using Sequencher (GeneCodes),
MacVector and GCG programs.
2.2. Northern blot analysis
The identical probe used for cDNA library screening was used to
assess the expression of O-sarcoglycan mRNA in multiple human tis-
sues. The PCR product was ampli¢ed in the presence of 32P-K-dCTP.
The radiolabeled product was used against 2 Wg of poly(A) RNA
from multiple human tissues (Clontech) as described [8].
2.3. Radiation hybrid mapping
To determine the map location of O-sarcoglycan the Genebridge 4
radiation hybrid panel (Research Genetics) was ampli¢ed as follows:
25 ng of each hybrid was ampli¢ed using 5P-CTTAGCAGGATCTC-
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TAATTATC-3P and 5P-GCAAGTGTCCACCTATCAGG-3P as the
primers in a 10 Wl reaction volume using 0.1 ng of each primer per
reaction using AmpliTaq Gold (Perkin Elmer Applied Biosystems).
The entire reaction volume was separated on 2% agarose gels and
stained with ethidium bromide. The reactions were scored as positive
(1), negative (0) or indeterminate (2). The map position was deter-
mined using Whitehead Institute RHmapper (http://www-genome.wi.
mit.edu/cgi-bin/contig/rhmapper.pl). Analysis was conducted using
a LOD score of s 3.0. Primers 5P-CATAGAATTCATTGAGA-
TGCAGTC-3P and 5P-AAGTGAGACACAGGAAGTGTTGATG-3P
were designed to amplify and map pseudo-O-sarcoglycan. The results
were similarly scored.
2.4. Mapping the murine O-sarcoglycan gene
Primers, 5P-GTTTATGTCATGGTTGGTGCCGATG-3P (2F) and
5P-TACTTCCTGATAGGTGGACACTTGC-3P (1R), to the EST
AA051289, were used with 100 ng of mouse genomic DNA
(C57BL/6J) with Takara (Panvera) according to the manufacturer’s
recommendations at 68‡C and 10 min extensions. A 3 kbp portion of
the murine O-sarcoglycan gene was reampli¢ed and directly sequenced
to determine that it contained a portion of O-sarcoglycan. The 2F
primer (listed above was used with a primer directed at intron 6 (5P-
TTCCAACAGCAATTCGGGTTCC-3P, primer 3R), in a PCR reac-
tion with the parental strains in the Jackson Labs BSS and BSB
mapping panels [10]. 25 ng of DNA was ampli¢ed using 10 ng of
each primer in a 10 Wl reaction volume in the presence of 32P-K-
dCTP as described [9]. The products were separated under non-dena-
turing conditions using 0.5UMDE (FMC Bioproducts), 1% glycerol.
A 40 cm gel was run at 7 W until the products had migrated to the
center of the gel. Gels were dried and autoradiographed for 12^24 h at
380‡C. The results were scored blind and submitted to Jackson Labs
for mapping.
2.5. Genotyping
Primers were designed to amplify the CA repeat found 3P of exon 3
of O-sarcoglycan. The primers ESG-E3-3C (5P-GTTATCTACT-
GTGTTTCCATGCAC-3P) and ESGE3-F2 (5P-CAACAATCATTG-
AGGTAATTTACACC-3P) were used to amplify 50 ng genomic
DNA in a 10 Wl volume as described [11] with the addition of 8%
DMSO. The cycling parameters were as follows: 10 min at 94‡C,
1 min at 55‡C, 30 s at 72‡C and 20 s at 94‡C for a total of 35 cycles.
The PCR products were separated on an ABI 377 sequencer and
the allele sizes were calculated using Genescan and Genotyper (Perkin
Elmer Applied Biosystems). The allele frequencies were deter-
mined from a panel of 45 normal, unrelated individuals of mixed
ethnicity.
3. Results
3.1. O-Sarcoglycan gene and mRNA expression
Sequences homologous to K-sarcoglycan were detected in
the electronic database of expressed sequence tags (ESTs).
The plasmid containing the EST N44285 (clone 273055) was
obtained and sequenced to con¢rm its content. This cDNA
encoded approximately 500 bp of O-sarcoglycan and showed
high homology to the predicted cytoplasmic domain of K-sar-
coglycan. A portion of this cDNA was used as a radioactive
probe against a panel of poly(A) mRNA from multiple hu-
man tissues (Fig. 1). A 1.7 kbp mRNA was detected in all
human tissues surveyed. To obtain full length clones encoding
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Table 1
Intron-exon boundaries of O-sarcoglycan
E1 tggacgggacagggtcgggggacacgcaggATGAGCCCCGCG ..... TCTTGCTGACAGgttagtggcctgcgcgcgacgtggaggtcc
M S P A F L L T
E2 ctgtcacttatctttcctctttgttttcagTGTACAGTATTT ..... ACCCAAAACCTGgtatgttctttgtgaggaaaaaaaagcagt
V Y S I Y P K P
E3 ttatgtcttaattctctgtttcttatctagGCGAGATTAGTA ..... ACAATCATAGAGgtaatttacacctagaaagagcaaaactat
G E I S T I I E
E4 ttctttaatatggttttccttttataatagATAACTGCCTAC ..... TGTCTGCAGAAGgtaggtatgaaaatatgttgatcatttctt
I T A Y S A E D
E5 gatatgcatgccctttttcaccaaaattagACTTCCCGTTGC ..... CCTGAAGGAGGGgtaagcagatctttatctcattgccttaaa
D F P L L K E G
E6 ggataacctgagagtttcacatttttacagCGTTTATGTCAT ..... AAAATTTCATTGgtaagtttttattttgtttttgcaagttta
V Y V M K I S L
E7 ttgttgtgtaattgtcttcttttatatcagGTTGATAAAACA ..... ACGGGAAGGCGTgtgagtactttaaaactaataagataatta
V D K T R E G V
E8 tttaattcataaattttgttttgtttctagGGAAAAGAGAAA ..... GCAAACACCAGAgtaagtgtcttctttcctgttattttcttc
E K R N Q T P D
E9 tatatgttgttttatttctttttgacctagCATCCAACTGGT ..... GCAAACGCAGCAgtaagtgtccacttagagccataattatta
I Q L V Q T Q Q
E11 gttttactcaaaaatgttcatcatttctagGAACTTGCCACA ..... AGCAGACTACAGgtgagtgctaagaataataaattaatgttt
N L P H Q Q T T
E12 cctgcccatattcattcttacacattgcagGTAAATGGTATC ..... CCTGAagaaagaaaactgactgaagcaatgaatttataatca
G K W Y P *
Exon numbers are indicated on the left. Translated nucleotides are shown capitalized. A minority of O-sarcoglycan transcripts contain exon 10.
Exon 10 (boundaries not determined) arises from splicing involving an Alu repeat.
Fig. 1. Expression of O-sarcoglycan mRNA in multiple human tis-
sues. Shown above is 2 Wg of poly(A) mRNA hybridized with a
portion of the O-sarcoglycan cDNA. A 1.7 kbp mRNA is seen in all
tissues.
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O-sarcoglycan, this same probe was used to screen a human
heart cDNA library. Four cDNA clones were plaque puri¢ed
and characterized by restriction digest, PCR and partial se-
quence data. Of these, one clone was fully sequenced to de-
termine the O-sarcoglycan nucleotide sequence and this se-
quence has been deposited in GenBank with the accession
number AF036364.
Within the coding region, O-sarcoglycan is 47% homologous
to K-sarcoglycan at the nucleotide level, and 62% similar at
the protein level (43% identical). The predicted amino acid
sequence of O-sarcoglycan is shown in Fig. 2. Like K-sarcogly-
can, there is a predicted hydrophobic signal sequence followed
by a substantial extracellular domain with a conserved con-
sensus site for asparagine-linked glycosylation [7,8] ; the site
for glycosylation is within the highly conserved region en-
coded by exon 5. There are four conserved cysteine residues
encoded by exon 6. It has been suggested that these residues
are important for function since mutations in the homologous
cysteine residues in K-sarcoglycan result in muscular dystro-
phy [1,2]. There is a hydrophobic transmembrane domain
followed by a short cytoplasmic domain. An alternative cyto-
plasmic domain was also seen in a second cDNA and its
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Fig. 2. Comparison of K-sarcoglycan and O-sarcoglycan predicted protein sequences. The amino acid sequences of K-sarcoglycan and O-sarcogly-
can are shown in A. The placement of the introns is also indicated by arrows. The nearly identical placement of the intron sequences suggests
that these two genes may have arisen from a gene duplication event. The hydrophobic transmembrane domain is highlighted. B shows an addi-
tional exon that is found to be present in a small percentage of O-sarcoglycan mRNA.
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sequence is shown in Fig. 2B. This alternative cytoplasmic
domain arises from the inclusion of exon 10. Of note, the
sequences within exon 10 have homology to the Alu class of
repetitive DNA sequences suggesting that the inclusion of
exon 10 may result from splicing that includes an Alu repeat.
Of the four cDNAs isolated, three represented the splice form
without exon 10. The predicted molecular mass of O-sarcogly-
can, without exon 10 and post-translational modi¢cations, is
47 kDa, and the calculated pI is 5.78, very close to the pre-
dicted pI (5.44) of K-sarcoglycan.
3.2. Genomic structure of O-sarcoglycan
The gene structure of O-sarcoglycan was determined from
genomic phage and is shown in Fig. 3. The positions of the
introns are highly conserved between K-sarcoglycan and O-
sarcoglycan as indicated by the arrows in Fig. 2. The sizes
of the introns in O-sarcoglycan were estimated by performing
long range PCR reactions with intra-exonic primers as well as
looking for overlapping fragments of the genomic phage en-
coding O-sarcoglycan (data not shown). The exact size of the
K-sarcoglycan gene is not known, but exons 2^9 are found
within a 10 kbp region ([7], E.M. McNally and L.M. Kunkel,
unpublished results). In comparison, the O-sarcoglycan gene is
estimated to span 50^100 kbp. This increase in size is due to
markedly larger introns. The sequences £anking each of the
exons are shown in Table 1. A polymorphic dinucleotide CA
repeat was found 3P of exon 3. Primers amplifying this repeat
were tested on the genomic DNA from 45 unrelated individ-
uals of mixed ethnicity. This microsatellite repeat was hetero-
zygous in 49% of the individuals tested, and the allele frequen-
cies are shown in Table 2.
3.3. Map position
The map position of O-sarcoglycan was determined using
primers speci¢c for exon 7 and intron 7 against a panel of
radiation hybrids (Genebridge 4, Research Genetics). This
primer pair was used to avoid amplifying the related locus,
pseudo-O-sarcoglycan (see below). With a LOD score s 3.0,
the results of the radiation mapping panel is shown in Fig. 4.
This places O-sarcoglycan near the marker D7S644 and
D7S657.
A cDNA encoding murine O-sarcoglycan was identi¢ed in
the electronic database (EST AA051289, clone 478626) and
the murine O-sarcoglycan gene was partially characterized us-
ing long range PCR with primers complementary to coding
region in exons 6 and 7. No evidence for an O-sarcoglycan
pseudogene was seen in the mouse genome. The map position
of murine O-sarcoglycan was determined by amplifying a por-
tion of the murine O-sarcoglycan gene from mouse genomic
DNA using primers to exon 6 and intron 6. Species speci¢c
PCR products were detected using SSCP analysis. The Jack-
son Labs Backcross panels BSB (backcross to C57BL/6J) and
BSS (backcross to M. spretus) were analyzed using this ap-
proach. The resulting map position is shown in Fig. 4. Both
mapping panels gave similar results. This places the murine O-
sarcoglycan gene near the telomere of chromosome 6. Several
other genes for which the human homologs are found at 7q21
are also in this region. The mapping of O-sarcoglycan extends
the synteny of this region.
3.4. Pseudo-O-sarcoglycan
Two of the phage clones isolated shared overlapping restric-
tion fragments and appeared to contain large fragments of the
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Fig. 4. The map position of human and murine O-sarcoglycan was determined using radiation hybrid mapping for the human O-sarcoglycan
gene and the Genebridge 4 Radiation Hybrid mapping panel. A processed pseudogene for O-sarcoglycan was detected on chromosome 2q21,
and its map position is shown. The position of the mouse O-sarcoglycan gene was determined using the Jackson Labs Backcross panel. The
mouse O-sarcoglycan gene maps to the syntenic region of human chromosome 7q21, mouse chromosome 6. cR, centiRay; cM, centiMorgans.
Fig. 3. The gene structure of O-sarcoglycan. Shown above is a schematic of the intron-exon boundaries of the O-sarcoglycan gene. Genomic
phage encoding exons of O-sarcoglycan were isolated and sequenced to determine the intron-exon boundaries. Phage that contained overlapping
fragments are indicated on the upper line. The size of most of the introns could not be determined using long range PCR which suggests that
the minimum size of the O-sarcoglycan gene is 50 kbp.
E.M. McNally et al./FEBS Letters 422 (1998) 27^3230
O-sarcoglycan gene based on hybridization with primers to O-
sarcoglycan. Sequence from these clones revealed what ap-
pears to be a processed pseudogene for O-sarcoglycan. Several
contiguous exons are present but an intact open reading frame
is not present (data not shown). The phage encoding pseudo-
O-sarcoglycan were used in £uorescence in situ hybridization
against human metaphase chromosomes and showed hybrid-
ization to chromosome 2q21 (data not shown). To con¢rm the
map position of the pseudo-O-sarcoglycan, primers designed
speci¢cally to amplify the pseudogene, as opposed to the chro-
mosome 7-encoded O-sarcoglycan, were used against the
Genebridge 4 Radiation hybrid panel. With a LOD score
s 3.0, pseudo-O-sarcoglycan maps near markers on chromo-
some 2. The results of the radiation hybrid mapping are
shown in Fig. 4.
4. Discussion
We have isolated a gene, O-sarcoglycan, that predicts a pro-
tein highly related to K-sarcoglycan [7,8]. Sequence analysis of
cDNAs encoding O-sarcoglycan suggests that O-sarcoglycan
and K-sarcoglycan share a similar structure. Both sequences
predict a hydrophobic signal sequence followed by an extra-
cellular domain with highly conserved cysteine residues. There
is some divergence in the predicted cytoplasmic domains sug-
gesting that these proteins may bind di¡erent partners in the
cytoplasmic side of the membrane. The overall gene structure
is conserved with nearly identical placement of introns sug-
gesting that these genes arose from a gene duplication event.
The lower homology seen at the nucleotide level than the
amino acid comparisons suggests that there has been selective
pressure on the protein sequence. The redundancy in the
DGC is striking and includes {dystrophin/utrophin} [12,13],
{Q-sarcoglycan/N-sarcoglycan} [14,15], {K-syntrophin/L1-syn-
trophin/L2-syntrophin} [16,17] and, now, {K-sarcoglycan/O-
sarcoglycan}. It is surprising that this system, with it marked
redundancy, can be the target of mutations that give rise to
such severe phenotypes as those seen in the muscular dystro-
phies. These proteins, while similar in structure, appear to
have critical and unique roles for muscle function.
Mutations in K-, L-, Q- and N-sarcoglycan have been de-
scribed in patients with autosomal recessive muscular dystro-
phy [1,2]. It may be that O-sarcoglycan is similarly mutated in
patients with muscular dystrophy. However, unlike K-, Q- and
N-sarcoglycan, O-sarcoglycan mRNA appears to be highly ex-
pressed in many human tissues [7,8,14,15]. In particular, the
mRNA for O-sarcoglycan is abundant in human placenta sug-
gesting that this gene and its product may be important in
human development. The dystrophin-associated protein, dys-
troglycan, shares a similar expression pattern to O-sarcoglycan
[5], and no patients have been described with dystroglycan
gene mutations. Mice homozygously lacking dystroglycan
die at embryonic day 6.5 [18]. Immunostaining with anti-dys-
troglycan antibodies suggests that, normally, dystroglycan is
abundantly present in the extraembryonic structure, Reich-
ert’s membrane [18]. This membrane is disrupted in animals
lacking dystroglycan, and this may lead to the early embry-
onic lethal phenotype. Because O-sarcoglycan is so highly ex-
pressed in non-muscle tissues, like dystroglycan, mutations in
this gene may have a more profound phenotype than muta-
tions in the genes expressed more exclusively in muscle tissue.
The similar expression pattern of O-sarcoglycan and dystrogly-
can suggests that these proteins may constitute the DGC as it
exists outside muscle.
The human map location of the O-sarcoglycan gene suggests
a possible involvement in the Split Hand/Split Foot deformity
syndrome (SHSF). In some cases, this is an autosomal dom-
inant disorder that has been re¢ned to a locus involving the
marker D7S644 [19]. Based on the map location, O-sarcogly-
can may be deleted in some SHSF patients. DLX5, a member
of the distal-less homeobox protein family, has been mapped
to the critical interval for SHSF [19]. However, the variably
severe phenotype argues that more than one gene may be
implicated in the development of this disorder. Haploinsu⁄-
ciency has not been seen to result in a phenotype in the het-
erozygous parents of patients with known sarcoglycan gene
mutations. The information presented here should facilitate
the study of this gene and its protein product in patients
with muscular dystrophy and other developmental disorders.
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